T2 Biosystems shares are trading higher after the FDA granted Breakthrough Device designation for the company's Candida auris direct-from-blood molecular diagnostic test.
Portfolio Pulse from Benzinga Newsdesk
T2 Biosystems has received Breakthrough Device designation from the FDA for its Candida auris direct-from-blood molecular diagnostic test. This has led to an increase in the company's share price.
July 20, 2023 | 12:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
T2 Biosystems' stock is trading higher following the FDA's Breakthrough Device designation for its Candida auris diagnostic test.
The FDA's Breakthrough Device designation is a significant regulatory milestone that can accelerate the development and review process for innovative medical devices. This positive news is likely to boost investor confidence in T2 Biosystems, leading to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100